Premium
YS Biopharma Company Ltd (YS)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is als... YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminum-free lyophilized rabies vaccine that was launched in China. Show more
GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global leader in the discovery, development...
YS Biopharma Announces Name Change to LakeShore Biopharma PR Newswire GAITHERSBURG, Md., May 24, 2024 GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS...
YS Biopharma Announces Results of Extraordinary General Meeting PR Newswire GAITHERSBURG, Md., May 21, 2024 GAITHERSBURG, Md., May 21, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS...
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer PR Newswire GAITHERSBURG, Md., May 7, 2024 GAITHERSBURG, Md...
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire GAITHERSBURG, Md., April 29, 2024 GAITHERSBURG, Md., April 29, 2024...
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 PR Newswire GAITHERSBURG, Md., April 19, 2024 GAITHERSBURG, Md., April 19, 2024 /PRNewswire/ -- YS...
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine PR Newswire GAITHERSBURG, Md., April 18, 2024 GAITHERSBURG, Md., April 18, 2024 /PRNewswire/...
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 PR Newswire GAITHERSBURG, Md., April 16, 2024 GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS...
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine PR Newswire GAITHERSBURG, Md., April 9, 2024 GAITHERSBURG, Md., April 9, 2024 /PRNewswire/...
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility PR Newswire GAITHERSBURG, Md., April 3, 2024 GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq:...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
